Development of LanthaScreen™ Cellular Assays for Key Components within the PI3K/AKT/mTOR Pathway
Authors:
- Coby B. CarlsonCCCoby B. Carlson
- Matthew B. RobersMRMatthew B. Robers
- Kurt W. VogelKVKurt W. Vogel
- Thomas MachleidtTMThomas Machleidt
Open Access
- 1 February 2009
- journal article
- research article
- Published by Elsevier in SLAS Discovery
- Vol. 14 (2) , 121-132
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Optimization and Utilization of the SureFire Phospho-STAT5 Assay for a Cell-Based Screening CampaignASSAY and Drug Development Technologies, 2008
- The Proline-rich Akt Substrate of 40 kDa (PRAS40) Is a Physiological Substrate of Mammalian Target of Rapamycin Complex 1Journal of Biological Chemistry, 2007
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Evidence for functional redundancy of class IA PI3K isoforms in insulin signallingBiochemical Journal, 2007
- Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?Oncogene, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Transfected Cell Lines as Tools for High Throughput Screening: A Call for StandardsSLAS Discovery, 2001
- A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysSLAS Discovery, 1999